

DAFTAR PUSTAKA

1. Iolascon G, Giménez S, Mogyorósi D. A review of aceclofenac: Analgesic and anti-inflammatory effects on musculoskeletal disorders. *J Pain Res.* 2021;14:3651–63.
2. Sipos E, Kósa N, Kazsoki A, Szabó ZI, Zelkó R. Formulation and characterization of aceclofenac-loaded nanofiber based orally dissolving webs. *Pharmaceutics.* 2019;11(8):1–11.
3. Dooley M, Spencer CM, Dunn CJ. Aceclofenac: A reappraisal of its use in the management of pain and rheumatic disease. *Drugs.* 2001;61(9):1351–78.
4. Shoaib MH, Aslam N, Muhammad IN. Aceclofenac: a new effective and safe NSAID. 2013;(January).
5. Goud NR, Suresh K, Nangia A. Solubility and stability advantage of aceclofenac salts. *Cryst Growth Des.* 2013;13(4):1590–601.
6. Kumar S, Gupta A, Mishra C, Singh S. Synthesis, characterization and performance evaluation of aceclofenac-urea cocrystals. *Indian J Pharm Sci.* 2020;82(5):881–90.
7. Vadher AH, Parikh JR, Parikh RH, Solanki AB. Preparation and characterization of co-grinded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac. *AAPS PharmSciTech.* 2009;10(2):606–14.
8. Nurismi E, Rosaini H, Octavia dan MD. Review: Effect of Different Methods on the Multicomponents Crystal Formation from Medicinal Natural Ingredient Compounds. *Int J Pharm Sci Med.* 2021;6(5):32–9.
9. Kumar S, Nanda A. Pharmaceutical cocrystals: An overview. *Indian J Pharm Sci.* 2017;79(6):858–71.
10. Samineni R, Chimakurthy J, Sumalatha K, Dharani G, Rachana J, Manasa K, et al. Co-crystals: A review of recent trends in co crystallization of bcs class ii drugs. *Res J Pharm Technol.* 2019;12(7):3117–24.
11. Putri D. Review: Multi-Component Crystals: Cinnamic Acid As A Co-Former. *Int J Pharm Sci Med.* 2021;6(1):92–8.
12. Wahyuni S. Pembentukan Multikomponen Kristal Dari Aseklofenak dan L-glutamin. *Andalas University;* 2022.
13. Meilina R, Mukhtar R. Efek Antiinflamasi Ekstrak Etanol Rimpang Kunyit (*Curcuma domestica* Val.) pada Tikus Putih yang Diinduksi Karagenan. *J Healthc Technol Med.* 2019;4(1):111.

14. PubChem. Bethesda (MD): National Library of Medicine (US). National Center for Biotechnology Information. 2022.
15. Kala S, Juyal D. Preformulation and characterization studies of aceclofenac active ingredient. *Pharma Innov J.* 2016;5(9):110–9.
16. Jelsch C, Devi RN, Noll BC, Guillot B, Samuel I, Aubert E. Aceclofenac and interactions analysis in the crystal and COX protein active site. *J Mol Struct.* 2020;1205:1–54.
17. Vemuri VD, Lankalapalli S. Amino acid based Rosuvastatin cocrystals: Towards the improvement of physicochemical parameters. *J Cryst Growth.* 2021;570(June):126241.
18. Nugrahani I, Jessica MA. Amino acids as the potential co-former for co-crystal development: A review. *Molecules.* 2021;26(11).
19. Cerreia Vioglio P, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. *Adv Drug Deliv Rev.* 2017;117:86–110.
20. Almeida E Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS. Supersaturation Potential of Salt, Co-Crystal, and Amorphous Forms of a Model Weak Base. *Cryst Growth Des.* 2016;16(2):737–48.
21. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharm.* 2012;2012(100 mL):1–10.
22. Zaini E, Afriyani, Fitriani L, Ismed F, Horikawa A, Uekusa H. Improved solubility and dissolution rates in novel multicomponent crystals of piperine with succinic acid. *Sci Pharm.* 2020;88(2).
23. Grothe E, Meekes H, Vlieg E, Ter Horst JH, De Gelder R. Solvates, Salts, and Cocrystals: A Proposal for a Feasible Classification System. *Cryst Growth Des.* 2016;16(6):3237–43.
24. Nugrahani I, Parwati RD. Challenges and progress in nonsteroidal anti-inflammatory drugs co-crystal development. *Molecules.* 2021;26(14).
25. Serajuddin ATM. Salt formation to improve drug solubility. *Adv Drug Deliv Rev.* 2007;59(7):603–16.
26. Clarke HD. Crystal Engineering of Multi-Component Crystal Forms: The Opportunities and Challenges in Design. *ProQuest Diss Theses.* 2012;(January):153.
27. Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. *Adv Drug Deliv Rev.* 2017;117:25–46.

28. Pawar N, Saha A, Nandan N, Parambil J V. Solution cocrystallization: A scalable approach for cocrystal production. *Crystals*. 2021;11(3).
29. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: An overview. *Int J Pharm*. 2011;419(1–2):1–11.
30. Patole T, Deshpande A. Co-Crystallization-a Technique for Solubility Enhancement. *Int J Pharm Sci Res*. 2014;5(9):3566.
31. Sathisaran I, Dalvi SV. Engineering cocrystals of poorly water-soluble drugs to enhance dissolution in aqueous medium. *Pharmaceutics*. 2018;10(3).
32. Schultheiss N, Newman A. 2009 Reviews. *Cryst Growth & Design*. 2009;9(6):2950–67.
33. Sari YN, Zaini E, Ismed F. Peningkatan Laju Disolusi Piperine dengan Pembentukan Multikomponen Kristal Menggunakan Asam Nikotinat. *J Sains Farm Klin*. 2019;6(2):180.
34. Yamashita H, Hirakura Y, Yuda M, Teramura T, Terada K. Detection of cocrystal formation based on binary phase diagrams using thermal analysis. *Pharm Res*. 2013;30(1):70–80.
35. Sudiono J. Sistem kekebalan tubuh. Penerbit Buku Kedokt EGC. 2014;(June):18–37.
36. Rosales C, Uribe-Querol E. Phagocytosis: A Fundamental Process in Immunity. *Biomed Res Int*. 2017;2017.
37. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell types? *Front Physiol*. 2018;9(FEB):1–17.
38. Flannagan RS, Jaumouillé V, Grinstein S. The cell biology of phagocytosis. *Annu Rev Pathol Mech Dis*. 2012;7:61–98.
39. Hupitoyo MS. *Biokimia Darah*. Vol. 21. Jakarta; 2019. 303 p.
40. Abdulkhaleq LA, Assi MA, Abdullah R, Zamri-Saad M, Taufiq-Yap YH, Hezmee MNM. The crucial roles of inflammatory mediators in inflammation: A review. *Vet World*. 2018;11(5):627–35.
41. Rodak Bernadette F CJH. *Clinical Hematology Atlas*. Fifth Edit. Vol. 123, Archives of Pathology & Laboratory Medicine. Elsevier Inc.; 2017. 278 p.
42. Purnomo Y, Tilaqza A. Analgesic and Anti-inflammatory Activities of *Urena lobata* L. Leaf Extracts. *Indones J Pharm*. 2022;33(4):566–74.
43. Suralkar AA, Rodge KN, Kamble RD, Maske KS. Evaluation of anti-inflammatory and analgesic activities of *Tamarindus indica* seeds. *Int J Pharm Sci Drug Res*. 2012;4(3):213–7.

44. Andersson J. The inflammatory reflex - Introduction. *J Intern Med.* 2005;257(2):122–5.
45. Mohan H. Textbook of Pathology. Textbook of Pathology. 2010.
46. White M. Mediators of inflammation and the inflammatory process. *J Allergy Clin Immunol.* 1999;103(3 SUPPL.):378–81.
47. Kanova M, Kohout P. Serotonin—its synthesis and roles in the healthy and the critically ill. *Int J Mol Sci.* 2021;22(9).
48. Golias C, Charalabopoulos A, Stagikas D, Charalabopoulos KA, Batistatou A. The kinin system-bradykinin: Biological effects and clinical implications. Multiple role of the kinin system-bradykinin. *Hippokratia.* 2007;11(3):124–8.
49. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget.* 2018;9(6):7204–18.
50. Dinarello CA. Proinflammatory cytokines. *Chest.* 2000;118(2):503–8.
51. Alshaikh RA, Essa EA, El Maghraby GM. Eutexia for enhanced dissolution rate and anti-inflammatory activity of nonsteroidal anti-inflammatory agents: Caffeine as a melting point modulator. *Int J Pharm.* 2019;563(April):395–405.
52. Drugs.com. L-glutamine dosage [Internet]. Available from: <https://www.drugs.com/monograph/l-glutamine.html#dosage>
53. Suryandari SS, Queljoe E De, Datu OS. Uji Aktivitas Antiinflamasi Ekstrak Etanol Daun Sesewanua (*Clerodendrum squamatum* Vahl.) Terhadap Tikus Putih (*Rattus norvegicus* L.) yang Diinduksi Karagenan. *Pharmacon.* 2021;10(3):1025–32.
54. Bangsawan Pandu Indra S. Uji Efek Antiinflamasi Kombinasi Astaxanthin dan Vitamin A terhadap Jumlah Neutrofil dan Limfosit pada Tikus Putih Galur Wistar yang diinduksi Karagenin. 2015;1(November):332–43.
55. Pharmacopeia E. European Directorate for the Quality of Medicines & Healthcare. 2010;1306–7.
56. Bazzo GC, Pezzini BR, Stulzer HK. Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs. *Int J Pharm [Internet].* 2020;588(August):119741. Available from: <https://doi.org/10.1016/j.ijpharm.2020.119741>
57. Jacobs A, Amombo Noa FM. Co-crystals and co-crystal hydrates of vanillic acid. *CrystEngComm.* 2015;17(1):98–106.

58. Chadha R, Kuhad A, Arora P, Kishor S. Characterisation and evaluation of pharmaceutical solvates of Atorvastatin calcium by thermoanalytical and spectroscopic studies. *Chem Cent J*. 2012;6(1):1–15.
59. Yadav A V., Shete AS, Dabke AP, Kulkarni P V., Sakhare SS. Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients. *Indian J Pharm Sci*. 2009;71(4):359–70.
60. Hardani R. Anti-Inflammatory Activity Test of Ethanolic Extract of Banana Leaf (*Musa Paradisiaca* L.) On Carrageenan. *Galen J Pharm* 126 *J Pharm*. 2015;1(2):126–32.
61. Fitriyani A, Winarti L, Muslichah S, Nuri D. Anti-Inflammatory Activityy Of Piper Crocatum Ruiz & Pav. Leaves Metanolic Extract In Rats. *Maj Obat Tradis*. 2011;16(1):2011.
62. Tomislav Friscic, Scott L. Childs SAAR and WJ. The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcoe. *CrystEngComm*. 2009;11(3):418–26.

